Table 2.
Individual hyaluronic acid levels of all patients included in this pilot study (n = 9) showing high inter-individual differences across the 3 weeks of therapy, even at baseline levels.
| ID | Diagnosis | Stage | Plasma hyaluronic acid levels (ng/mL) |
|
|---|---|---|---|---|
| Pre-CDT | Post-CDT | |||
| 1 | Secondary benign leg lymphedema left | II–III | 5.19 | 14.22 |
| 2 | Primary leg lymphedema both sides | III | 34.39 | 75.99 |
| 3 | Primary leg lymphedema left | II | 3.83 | 4.66 |
| 4 | Primary leg lymphedema both sides | III | 240.68 | 34.30 |
| 5 | Primary leg lymphedema both sides | II | 2.73 | 3.98 |
| 6 | Secondary benign leg lymphedemaboth sides | II | 54.37 | 24.36 |
| 7 | Primary leg lymphedema both sides | III | 5.86 | 5.92 |
| 8 | Chronic secondary leg lymphedemaboth sides | II | 5.28 | 11.75 |
| 9 | Chronic leg lymphedema both sides | II–III | 14.51 | 20.88 |
| Median | 7.30 | 12.98 | ||
| IQR | 4.85–39.38 | 5.60–26.85 | ||
| Min-max | 2.73–240.68 | 3.98–75.99 | ||
| p-value | Pre-CDT vs post-CDT: 0.333 | |||